To hear about similar clinical trials, please enter your email below
Trial Title:
The Use of a Quality of Life Questionnaire in Patients With Lung Cancer
NCT ID:
NCT01213745
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Conditions: Keywords:
lung
cancer
quality of life
Study type:
Interventional
Study phase:
N/A
Overall status:
Unknown status
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
Single (Investigator)
Intervention:
Intervention type:
Other
Intervention name:
Intervention
Arm group label:
Intervention
Intervention type:
Other
Intervention name:
Attention
Arm group label:
Attention
Intervention type:
Other
Intervention name:
Control
Arm group label:
Control
Summary:
This study will investigate the effectiveness of using the European Organisation for
Research and Treatment of cancer Core Quality of Life Questionnaire (EORTC QLQ-C30 + LC
13) to identify and target therapies in patients with lung cancer. The study will assess
whether using the questionnaire will result in an improvement in QoL.
Detailed description:
Patients with lung cancer who have completed a course of treatment (or who are in-between
treatment) at the Royal Marsden Hospital would be eligible for inclusion in the study.
Participants will be randomised into 3 groups. Group 1 - this group will complete the QoL
questionnaire and will receive targeted therapies by a doctor (and other members of the
oncology team) during a clinic consultation. Group 2 - will complete the QoL
questionnaire however the questionnaire will not be seen by the doctor during a clinic
consultation. Group 3 - the control group will not complete the QoL questionnaire before
a clinic consultation. All patients will complete a diary of all contact they have with
health care professionals during the study. The study will last for 6 weeks and at the
end of the study all patients will complete the QoL questionnaire.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- male or female age > 18 years
- patients who are able to adequately understand written and spoken english
- diagnosis of lung cancer (non small cell, small cell, mesothelioma)
- no plan to commence treatment (chemotheraphy, targeted therapies, radioterhapy,
surgery) with 6 weeks
- both radically or palliatively treated patients remain eligible
- patients whose toxicities from their primary treatment has resolved or have
stabilised for a period of 7 days
Exclusion Criteria:
- patients are taking part on any other QoL studies
- taking part in any other studies that requires QoL questionnaires, extra visits or
investigations
- currently on treatment (chemotherapy, radiotherapy, surgery or targeted therapies)
- they have on going toxicities from their treatment which have not been stablised
(required intervention within last 7 days)
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Royal Marsden NHS Foundation Trust
Address:
City:
Sutton
Zip:
SM2 5PT
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
Dr M O'Brien
Phone:
02086613278
Email:
mary.o'brien@rmh.nhs.uk
Contact backup:
Last name:
Mr M Laybourne
Phone:
02086613835
Email:
matthew.laybourne@rmh.nhs.uk
Investigator:
Last name:
Dr Mary O'Brien
Email:
Principal Investigator
Start date:
September 2010
Completion date:
July 2012
Lead sponsor:
Agency:
Royal Marsden NHS Foundation Trust
Agency class:
Other
Source:
Royal Marsden NHS Foundation Trust
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01213745
